(VIANEWS) – Shares of PCI BIOTECH HOLD (Oslo Børs Benchmark Index_GI: PCIB.OL) jumped by a staggering 10.44% to kr1.99 at 11:38 EST on Monday, after three consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI is sliding 0.4% to kr1,226.66, after three sequential sessions in a row of gains. This seems, at the moment, a somewhat negative trend trading session today.
PCI BIOTECH HOLD’s last close was kr1.80, 69.8% below its 52-week high of kr5.96.
About PCI BIOTECH HOLD
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in pre-clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Olix Pharmaceuticals, Aposense, IMV Immunovaccine, MDimune, eTheRNA, and Immunicum. PCI Biotech Holding ASA was incorporated in 2007 and is based in Oslo, Norway.
Earnings Per Share
As for profitability, PCI BIOTECH HOLD has a trailing twelve months EPS of kr-1.02.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -53.97%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, PCI BIOTECH HOLD’s stock is considered to be overbought (>=80).
More news about PCI BIOTECH HOLD (PCIB.OL).
